Severity of influenza a(H1N1) illness and emergence of D225G variant, 2013–14 influenza season, Florida, USA

Emerging Infectious Diseases

Volumn 21, Issue 4, 2015, Pages 664-667

  Iovine, Nicole M ^a   Glenn Morris, J ^a   Fredenburg, Kristianna ^a   Rand, Kenneth ^a   Alnuaimat, Hassan ^a   Lipori, Gloria ^a   Brew, Joseph ^b   Lednicky, John A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b FLORIDA DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

D225G VARIANT; HEMAGGLUTININ; OSELTAMIVIR; PROTEIN; PROTEIN VARIANT; SIALYLGLYCAN; UNCLASSIFIED DRUG;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; COUGHING; DISEASE SEVERITY; FEMALE; FEVER; HUMAN; HUMAN TISSUE; INFLUENZA A (H1N1); LUNG HEMORRHAGE; LUNG INFILTRATE; LUNG INJURY; MALE; MIDDLE AGED; MORTALITY; PNEUMONIA; PROTEIN POLYMORPHISM; SORE THROAT; TRACHEITIS; UNITED STATES; ADOLESCENT; COMORBIDITY; GENETIC VARIABILITY; GENETICS; HISTORY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; LUNG; PATHOLOGY; SEASON; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; FLORIDA; GENETIC VARIATION; HISTORY, 21ST CENTURY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; LUNG; MALE; MIDDLE AGED; MORTALITY; SEASONS; YOUNG ADULT;

EID: 84924973184     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2104.141375     Document Type: Article

References (15)

1. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009. Influenza; Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362:1708–19. http://dx.doi.org/10.1056/NEJMra1000449
2. Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 2009;361:2507–17. http://dx.doi.org/10.1056/NEJMoa0906612
3. US Census Bureau. 2010. Census of population and housing, demographic profile summary file 1. 2010 [cited 2014. Aug 1]. http://www2.census.gov/census_2010/04-Summary_File_1/Florida/fl2010.sf1.zip
4. Centers for Disease Control and Prevention. People at high risk of developing flu-related complications. 2014 [cited 2014. Aug 1]. http://www.cdc.gov/flu/about/disease/high_risk.htm
5. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. 2008;3:499–522. http://dx.doi. org/10.1146/annurev.pathmechdis.3.121806.154316
6. Childs RA, Palma AS, Wharton S, Matrosovich T, Liu Y, Chai W, et al. Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol. 2009;27:797–9. http://dx.doi.org/10.1038/ nbt0909-797
7. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature. 2006;440:435–6. http://dx.doi.org/10.1038/440435a
8. Lednicky JA, Loeb JC. Detection and isolation of airborne influenza A H3N2 virus using a Sioutas Personal Cascade Impactor Sampler. Influenza Res Treat. 2013;2013:656825.
9. Lednicky JA, Wyatt DE. The art of animal cell culture for virus isolation. In: Ceccherini-Nelli L, Matteoli B, editors. Biomedical tissue culture. Zagreb (Croatia): InTech; 2012. p. 151–78.
10. Glaser L, Stevens J, Zamarin D, Wilson IA, García-Sastre A, Tumpey TM, et al. A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol. 2005;79:11533–6. http://dx.doi.org/10.1128/JVI.79.17.11533-11536.2005
11. Zhang W, Shi Y, Qi J, Gao F, Li Q, Fan Z, et al. Molecular basis of the receptor binding specificity switch of the hemagglutinins from both the 1918 and 2009 pandemic influenza A viruses by a D225G substitution. J Virol. 2013;87:5949–58. http://dx.doi.org/10.1128/JVI.00545-13
12. Chen H, Wen X, To KK, Wang P, Tse H, Chan JF, et al. Quasispecies of the D225G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009 virus from patients with severe disease in Hong Kong, China. J Infect Dis. 2010;201:1517–21. http://dx.doi.org/10.1086/652661
13. Galiano M, Agapow PM, Thompson C, Platt S, Underwood A, Ellis J, et al. Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. PLoS ONE. 2011;6:e23779. http://dx.doi.org/10.1371/journal.pone.0023779
14. Wu C, Cheng X, Wang X, Lv X, Yang F, Liu T, et al. Clinical and molecular characteristics of the 2009 pandemic influenza H1N1 infection with severe or fatal disease from 2009 to 2011 in Shenzhen, China. J Med Virol. 2013;85:405–12. http://dx.doi.org/10.1002/jmv.23295
15. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002; 55:307–17. http://dx.doi.org/10.1016/S0166-3542(02)00053-0